Document Detail


Isoprodian and rifampicin in the treatment of leprosy: a descriptive evaluation of therapy durations in 475 Paraguayan leprosy patients.
MedLine Citation:
PMID:  2676405     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In Paraguay, the National Leprosy/Tuberculosis Program is based on a combined chemotherapy with isoprodian and rifampicin. The aim of this descriptive study was to investigate the therapy durations used so far in the treatment of 475 leprosy patients and to analyze the criteria responsible for the wide-ranging differences in therapy durations. As initial criteria, the following parameters were identified to have a significant influence on the therapy duration: Patients never treated before or pretreated, clinical classification and initial bacteriological index (BI) value. During therapy, conditions like the attendance and BI decrease/year showed a significant correlation with the therapy duration. Even though the studied criteria did not allow to draw a definite conclusion with regard to an 'ideal' therapy duration, they proved to be reliable, as only 2 patients have relapsed so far.
Authors:
S Pritze; A E Alvarenga; O Leguizamon; I Haubitz
Related Documents :
22274735 - Changes in intraocular pressure during prone spine surgery under propofol and sevoflura...
22345765 - Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole...
22806415 - Influence of patient-controlled epidural analgesia versus patient-controlled intravenou...
22696145 - Clinical outcomes of open meniscal repair of horizontal meniscal tears in young patients.
22771055 - Shunt reintervention and time-related events after norwood operation: impact of shunt s...
22274735 - Changes in intraocular pressure during prone spine surgery under propofol and sevoflura...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chemotherapy     Volume:  35     ISSN:  0009-3157     ISO Abbreviation:  Chemotherapy     Publication Date:  1989  
Date Detail:
Created Date:  1989-11-21     Completed Date:  1989-11-21     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  373-82     Citation Subset:  IM    
Affiliation:
Armauer-Hansen-Institut, Würzburg, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Dapsone / therapeutic use*
Drug Combinations / therapeutic use
Drug Therapy, Combination
Humans
Isoniazid / therapeutic use*
Isonicotinic Acids / therapeutic use*
Leprostatic Agents / therapeutic use*
Leprosy / drug therapy*
Leprosy, Borderline / drug therapy
Leprosy, Lepromatous / drug therapy
Leprosy, Tuberculoid / drug therapy
Mycobacterium leprae / drug effects,  isolation & purification
Paraguay
Patient Compliance
Prothionamide / therapeutic use*
Rifampin / therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Drug Combinations; 0/Isonicotinic Acids; 0/Leprostatic Agents; 13292-46-1/Rifampin; 14222-60-7/Prothionamide; 54-85-3/Isoniazid; 55015-10-6/isoprodian; 80-08-0/Dapsone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potencies of ceftriaxone and cefotaxime in a single chamber pharmacokinetic system simulating their ...
Next Document:  Treatment of various infections in an outpatient practice by intramuscular ceftriaxone: home parente...